- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03633409
Differential EBI2 Expression Upon Allelic Status of the rs9557195 Polymorphism
Studieoversikt
Status
Forhold
Detaljert beskrivelse
EBI2 is a risk gene for inflammatory bowel diseases (rs9557195). EBI2 is a G protein coupled receptors expressed on the immune cells. EBI2 directs migration and activity of immune cells.
Patients of the Swiss IBD cohort study have been genotyped for the allelic status of EBI2. The investigators will recruit patients with Crohn's disease and ulcerative colitis, assess epidemiological and clinical parameters (including clinical activity of IBD) draw blood, isolate lymphocytes, DNA and RNA.
The investigators will test the influence of rs9557195 genotype (TT or CC allel), inflammatory activity and current treatment (infliximab vs. vedolizumab) on expression and activity of EBI2 on blood lymphocytes (by FACS using an EBI2-antibody), mRNA expression (by qPCR) of EBI2 and UBAC2 (located on the opposite DNA strand of EBI2) and activity of lymphocytes on a migration assay.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
-
Zurich, Sveits, 8091
- Rekruttering
- University Hospital Zurich
-
Ta kontakt med:
- Rene Roth, MD
- Telefonnummer: ++41 44 255 1111
- E-post: rene.roth@usz.ch
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
we will recruit a mixed population (patients can be in more than one group)
- up to 100 healthy volunteers
- up to 30 IBD patients with the rs9557195-CC IBD risk genotype in clinical remission
- up to 30 IBD patients with the rs9557195-CT IBD risk genotype in clinical remission
- up to 30 IBD patients with the rs9557195-TT IBD low risk genotype in clinical remission
- up to 50 IBD patients of any genotype during a flare
- up to 50 IBD patients of any genotype treated with vedolizumab
- up to 50 IBD patients of any genotype treated with a TNF-inhibitor (infliximab, adalimumab, golimumab, certolizumab)
Beskrivelse
Inclusion Criteria:
- Patient with IBD OR healthy volunteer
- No major uncontrolled medical/ surgical/ psychiatric condition requiring ongoing management besides IBD in the respective study groups. Well controlled conditions (i.e. medically controlled arterial hypertension, occupational asthma) may be present
Exclusion Criteria: none
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Tverrsnitt
Kohorter og intervensjoner
Gruppe / Kohort |
---|
IBD patients and healthy volunteers
We will recruit IBD patients and healthy volunteers
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
EBI2 expression - dependent on rs9557195 allele status (FACS)
Tidsramme: at time of inclusion into the study
|
EBI2 levels in PBMCs will be determined by FACS, and compared according to allele status of rs9557195
|
at time of inclusion into the study
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
EBI2 expression - dependent on rs9557195 allele status (RT-PCR)
Tidsramme: at time of inclusion into the study
|
EBI2 levels in PBMCs will be determined by RT-PCR, and compared according to EBI2 levels in PBMCs will be determined by RT-PCR, and compared according to allele status of rs9557195
|
at time of inclusion into the study
|
UBAC2 expression - dependent on rs9557195 allele status (RT-PCR)
Tidsramme: at time of inclusion into the study
|
UBAC2 levels in PBMCs will be determined by RT-PCR, and compared according to 2 levels in PBMCs will be determined by RT-PCR, and compared according to allele status of rs9557195
|
at time of inclusion into the study
|
Motility of PBMCs dependent on rs9557195 allele status (Boyden chamber)
Tidsramme: at time of inclusion into the study
|
motility of PBMCs will be assessed using the Boyden chamber and compared according to allele status of rs9557195
|
at time of inclusion into the study
|
EBI2-expression (FACS) in individuals treated with infliximab vs. vedolizumab
Tidsramme: at time of inclusion into the study
|
We will compare EBI2 expression as determined by FACS in individuals with infliximab and vedolizumab treatment
|
at time of inclusion into the study
|
EBI2-expression (FACS) according to gut inflammation
Tidsramme: at time of inclusion into the study
|
We will compare EBI2 expression (determined by FACS) in IBD patients with severe disease, in remission and in healthy volunteers
|
at time of inclusion into the study
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- EBI2-Study
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Inflammatoriske tarmsykdommer
-
University of ArkansasAvsluttetPediatriske pasienter med SIRS (Systemic Inflammatory Response Syndrome)Forente stater
-
Arkansas Children's Hospital Research InstituteEunice Kennedy Shriver National Institute of Child Health and Human Development...AvsluttetSIRS (Systemic Inflammatory Response Syndrome)Forente stater
-
Chinese PLA General HospitalFullførtSepsis | SIRS (Systemic Inflammatory Response Syndrome)Kina
-
Chinese PLA General HospitalUkjentSepsis | SIRS (Systemic Inflammatory Response Syndrome)Kina
-
Seoul National University HospitalUkjentSunn | Kronisk forstoppelse | Constipated Irritable Bowel Syndrome
-
Istanbul UniversityFullførtBetennelse | Type 2 diabetes | Medisinsk ernæringsterapi | Dietary inflammatory Index (DII)Tyrkia